Trial Profile
Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago-gastric Diseases (PROCEED)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Mar 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Carboplatin; Paclitaxel
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms PROCEED
- 20 Jan 2024 Results assessing safety and efficacy of Pembrolizumab, radiotherapy, and chemotherapy in neoadjuvant treatment of malignant esophago-gastric diseases presented at the 2024 Gastrointestinal Cancers Symposium
- 29 Nov 2023 Status changed from active, no longer recruiting to completed.
- 14 Sep 2023 Planned End Date changed from 23 Aug 2023 to 22 Nov 2023.